ClinicalTrials.gg
RecruitingNCT06255626Updated Apr 25, 2025

Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.

A Phase 1/2 interventional study of CD40.RBDv vaccin (SARS-Cov2 Vaccin) in COVID-19, sponsored by ANRS, Emerging Infectious Diseases. Recruiting at 2 sites in France. Open to participants aged 18 Years to 84 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-25.

Sponsored by ANRS, Emerging Infectious Diseases · Phase 1/2, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
215
Allocation
Randomized
Ages
18 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing mRNA COVID-19 Vaccine in COVID-19 — 3 open to participants now, 3 under way, none of them phase 3. mRNA COVID-19 Vaccine · COVID-19.

Planned enrollment
4th of 12
215 · median 157
Started
2024
the only one that year
Phase 1/2
2 of 12
1 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
ANRS, Emerging Infectious Diseases

Among the 12 studies testing mRNA COVID-19 Vaccine in COVID-19, this one is the 4th largest by planned enrollment, is the only one that started in 2024, is one of 2 in phase 1/2, and was the 11th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 12 studies testing mRNA COVID-19 Vaccine in COVID-19 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About mRNA COVID-19 Vaccine

mRNA COVID-19 Vaccine: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 84 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing mRNA COVID-19 Vaccine in COVID-19, or all of them as a file.
02

Study summary

The goal of this clinical trial, on healthy volunteers, is to learn more about safety and reactogenicity of the CD40.RBDv vaccine.

The main questions that will be studied are :

  • Is the CD40.RBDv (adjuvanted or not) safe ?
  • Does the CD40.RBDv (adjuvanted or not) imply an immunologic response ? Participants will receive, depending on their randomization arm, 1 or 2 injections of the CD40.RBDv vaccine or a single injection of approved mRNA vaccine
Read the detailed description

Phase 1/2a randomized, multicentre trial with four cohorts of two arms in two parts.

Part 1:

Cohort 1: Low dose (LD) CD40.RBDv vaccine non adjuvanted or mRNA vaccine (5:1 ratio)

Cohort 2: LD CD40.RBDv vaccine adjuvanted or mRNA vaccine (5:1 ratio)

Cohort 3: High dose (HD) CD40.RBDv vaccine non adjuvanted or mRNA vaccine (5:1 ratio)

Cohort 4: SC injection of HD CD40.RBDv vaccine adjuvanted or mRNA vaccine (5:1 ratio)

A substancial amendment (January 2025) has removed the randomisation to mRNA vaccine from the study design

Go-criterion for opening enrolment within cohorts are detailed into the protocol.

Part 2 at Month 3 :

Group 1: Volunteers who received mRNA vaccine in Part 1 will not receive any vaccine

Group 2: Volunteers who received a first dose of CD40.RBDv vaccine (adjuvanted or not) in Part 1 but randomized (1:1) to receive no further dose of vaccine in Part 2.

Group 3: Volunteers who received a first dose of CD40.RBDv vaccine (adjuvanted or not) in Part 1 and randomized (1:1) to receive an additional dose of CD40.RBDv vaccine (adjuvanted or not)

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • Vaccine
  • COVID-19
04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers Age ≥18 and \<85
  • Able to understand and comply with planned study procedures and sign an before performance of any study-related screening procedures
  • Who has received a primary series of vaccination and ≥ 1 booster(s) of COVID-19 mRNA vaccination(s) with the last boost at least 6 months prior to the inclusion in the study
  • Subjects has adequate organ functions, evidenced by normal , AST, and alkaline phosphatase
  • Normal haematology lab values
  • Negative virology assessment
  • Normal Urine testing
  • Volunteers must meet the eligibility criteria in the approved package labelling of the active comparator
  • For women of : use of an effective method and negative pregnancy test. For male participants, use of an effective method of contraception with their partner

Exclusion criteria

Exclusion Criteria:

  • Acute febrile infection within the previous 72 hours and/or presenting symptoms suggestive of COVID-19 or SARS CoV 2 infection within the previous 28 days
  • medications received within last three months before first IMP administration or within 6 months for chemotherapies
  • Immunoglobulins within 90 days before first IMP administration
  • Blood products within 120 days before first IMP administration
  • Any medical condition, such as cancer, that might impair the immune response
  • Use of any experimental therapy
  • Intent to participate in another study of an research agent within 4 weeks prior to the enrolment visit or until the end of the study
  • Currently pregnant or breastfeeding
  • History of severe adverse events following vaccine administration
  • Any bleeding disorder considered as a to an intramuscular injection
  • A condition that requires active medical intervention or monitoring to avert grave danger to Asthma other than mild, well-controlled asthma.
  • Hypertension
  • ≥ 40 kg/m2; ≤ 18 kg/m2; or BMI ≥ 35 kg/m2 with 2 or more of the following: age > 45, current smoker, known hyperlipidemia, blood pressure is defined as consistently ≥ 140 mm Hg systolic and ≥ 90 mm Hg diastolic
  • Asplenia
  • Seizure disorder
  • History of hereditary angioedema acquired angioedema, or idiopathic angioedema
  • History of myocarditis, pericarditis, cardiomyopathy, congestive heart failure with permanent sequelae, arrhythmia (including arrhythmia requiring medication, treatment, or clinical follow-up
  • History of disease
  • Any medical, occupational, or other condition that, in the judgment of the investigator, would interfere with or serve as a contraindication to protocol adherence
  • Psychiatric condition that precludes compliance with the protocol.
  • received within 30 days before first IMP administration or scheduled within 28 days after one of the last injection according to the protocol
  • Vaccines that are not live attenuated vaccines and were received within 21 days prior to first IMP administration
  • Allergy treatment with antigen injections within 30 days before first IMP administration and until the end of the study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
215 participants (estimated)

Study arms

  • Experimental
    1-CD40.RBDv non adjuvanted or mRNA vaccine (5:1 ratio)

    Low dose (LD) CD40.RBDv vaccine non adjuvanted or mRNA vaccine (5:1 ratio). If randomized to receive LD CD40.RBDv vaccine non adjuvanted in part 1, the subject will be randomised a second time to receive LD CD40.RBDv vaccine non adjuvanted (1:1) in part 2. Following a substancial amendment the randomization to mRNA vaccine has been removed from study design

    Drug: CD40.RBDv vaccin (SARS-Cov2 Vaccin)

  • Experimental
    2-CD40.RBDv vaccine adjuvanted or mRNA vaccine (5:1 ratio)

    LD CD40.RBDv vaccine adjuvanted or mRNA vaccine (5:1 ratio) If randomized to receive LD CD40.RBDv vaccine adjuvanted in part 1, the subject will be randomised a second time to receive LD CD40.RBDv vaccine adjuvanted (1:1) in part 2. Following a substancial amendment the randomization to mRNA vaccine has been removed from study design

    Drug: CD40.RBDv vaccin (SARS-Cov2 Vaccin)

  • Experimental
    3-High dose (HD) CD40.RBDv vaccine non adjuvanted or mRNA vaccine (5:1 ratio)

    High dose (HD) CD40.RBDv vaccine non adjuvanted or mRNA vaccine (5:1 ratio) If randomized to receive HD CD40.RBDv vaccine non adjuvanted in part 1, the subject will be randomised a second time to receive HD CD40.RBDv vaccine non adjuvanted (1:1) in part 2. Following a substancial amendment the randomization to mRNA vaccine has been removed from study design

    Drug: CD40.RBDv vaccin (SARS-Cov2 Vaccin)

  • Experimental
    4-High dose (HD) CD40.RBDv vaccine adjuvanted or mRNA vaccine

    HD CD40.RBDv vaccine adjuvanted or mRNA vaccine (5:1 ratio) If randomized to receive HD CD40.RBDv vaccine adjuvanted in part 1, the subject will be randomised a second time to receive HD CD40.RBDv vaccine adjuvanted (1:1) in part 2. Following a substancial amendment the randomization to mRNA vaccine has been removed from study design

    Drug: CD40.RBDv vaccin (SARS-Cov2 Vaccin)

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants without any grade 3 or 4 biological or clinical solicited local/systemic or unsolicited AEs between D1 and Month 3 after each IMP/vaccine administration and considered to be related or possibly related to IMP administration

    These proportions of participants will be described with its 95% two-sided confidence interval.

    Time frame: Month 3

  2. Neutralization antibodies titers (anti-RBD) against the original strain D614G and the relevant strain circulating at time of the study Month 1

    The primary immunogenecity endpoint is the neutralization antibodies titers (anti -RBD) against the original strain D614G and the relevant strain circulating at time of the study Month 1 after each dose The geometric mean titers (GMTs) with 95% confidence intervals (CIs) will be calculated at baseline and at Month 1 after each dose.

    Time frame: Month 1

Secondary outcomes

  1. Number of volunteers with solicited local and systemic Adverse Reactions (ARs)

    The original verbatim terms used by investigators to identify adverse events in the eCRF will be mapped to preferred terms using the MedDRA dictionary. The adverse events will then be grouped by MedDRA preferred terms into frequency tables according to system organ class. All reported adverse events, as well as adverse events judged by the investigator as at least possibly related to study vaccine, will be summarized according to system organ class and preferred term within system organ class and by interval of study observation. When an adverse event occurs more than once for a participants, the maximal severity and strongest relationship to the vaccine group will be chosen.

    Time frame: Day 8

  2. Number of volunteers with Adverse Events (AEs) other than solicited adverse events

    The original verbatim terms used by investigators to identify adverse events in the eCRF will be mapped to preferred terms using the MedDRA dictionary. The adverse events will then be grouped by MedDRA preferred terms into frequency tables according to system organ class. All reported adverse events, as well as adverse events judged by the investigator as at least possibly related to study vaccine, will be summarized according to system organ class and preferred term within system organ class and by interval of study observation. When an adverse event occurs more than once for a participants, the maximal severity and strongest relationship to the vaccine group will be chosen.

    Time frame: Day 1 to Months 3 after each dose

  3. Number of volunteers with Serious Adverse Events (SAEs), grade 3 and grade 4

    The original verbatim terms used by investigators to identify adverse events in the eCRF will be mapped to preferred terms using the MedDRA dictionary. The adverse events will then be grouped by MedDRA preferred terms into frequency tables according to system organ class. All reported adverse events, as well as adverse events judged by the investigator as at least possibly related to study vaccine, will be summarized according to system organ class and preferred term within system organ class and by interval of study observation. When an adverse event occurs more than once for a participants, the maximal severity and strongest relationship to the vaccine group will be chosen.

    Time frame: Day 1 to Months 3 after each dose

  4. Number of volunteers with events leading to discontinuation of the vaccine regimen

    The original verbatim terms used by investigators to identify adverse events in the eCRF will be mapped to preferred terms using the MedDRA dictionary. The adverse events will then be grouped by MedDRA preferred terms into frequency tables according to system organ class. All reported adverse events, as well as adverse events judged by the investigator as at least possibly related to study vaccine, will be summarized according to system organ class and preferred term within system organ class and by interval of study observation. When an adverse event occurs more than once for a participants, the maximal severity and strongest relationship to the vaccine group will be chosen. Separate summaries will be produced for the following categories: * Serious adverse events * Adverse events that are possibly or probably related to vaccine * Adverse event leading to withdrawal from the study * After any vaccination and by vaccination

    Time frame: Through study completion, an average of 15 months

  5. Seroconversion rate defined by an increase of 4 folds between day1 (baseline before vaccination) and Month 1 in anti-RBD IgG binding titers

    • The seroconversion rate defined by an increase of 4 folds between day1 (baseline before vaccination) and Month 1 in anti-RBD IgG binding titers will be described with its 95% two-sided confidence interval.

    Time frame: Month 1

  6. To assess the cross-neutralization against the most relevant VOCs at the time of the study

    • To assess the cross-neutralization against the most relevant VOCs, The geometric mean titers (GMTs) with 95% confidence intervals (CIs) will be calculated at each timepoint.

    Time frame: Day 1 (before each vaccination) day 8, day 14 and M1 after each vaccination, M3, M6, M12 (ie. 12 months after 1st dose and 9 months after 2nd dose) and M15 (ie. 15 months after 1st dose and 12 months after 2nd dose)

  7. To analyze the correlation between the magnitude of CD4+ specific T cell responses and levels of IgG specific responses

    • Correlation between the magnitude of CD4+ specific T cell responses and levels of igG specific responses will be estimated at each timepoint using Pearson or Spearman correlation coefficients, depending on variables distribution.

    Time frame: Day 1 (before each vaccination) day 14 after each vaccination, M3, M6, M12 (ie. 12 months after 1st dose and 9 months after 2nd dose) and M15 (ie. 15 months after 1st dose and 12 months after 2nd dose)

  8. To characterize the vaccine efficacy by evaluating the number of COVID-19 infections (PCR+) and severity (based on CDC definition) in participants throughout the study follow-up.

    • Number of COVID-19 infections (PCR+) and severity (based on CDC definition) throughout the study follow-up.

    Time frame: Through study completion, an average of 15 months

  9. To evaluate the Cytokine expression patterns of CD4 and CD8 T cells as measured by intracellular cytokine staining assay

    • Cytokine expression patterns of CD4 and CD8 T cells, measured by intracellular cytokine staining assay, will be described at each timepoint.

    Time frame: Day 1 (before each vaccination) day 14 after each vaccination, M3, M6, M12 (ie. 12 months after 1st dose and 9 months after 2nd dose) and M15 (ie. 15 months after 1st dose and 12 months after 2nd dose)

  10. Percentages of T cells producing at least one cytokine after in vitro stimulation

    • Recall memory T cell responses, following in vitro restimulation (Epimax technology) on residual samples and depending on the results obtained in the analysis of intracellular cytokine staining assay, will be described.

    Time frame: Through study completion, an average of 15 months

  11. Concentration (pg/mL) of cytokines produced by stimulated PBMC

    • Cytokines produced by stimulated PBMC (Luminex assay) on samples evaluated by Epimax technology will be described.

    Time frame: Through study completion, an average of 15 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Sep 2025, 16 months after the start.

Of 107 non-industry phase 1/2 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 16 months is above that.

Counting every sponsor, half of 187 studies reached it within 11 months; a quarter within 4 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2024
First posted
Feb 13, 2024
StartActual
May 27, 2024
Primary completionEst.
Sep 2025
CompletionEst.
Sep 2025
Last update
Apr 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06255626
Collaborators
Vaccine Research Institute (VRI), France, EnnoDc (previously known as LinKinVax)
Responsible party
Sponsor
First posted
Feb 13, 2024
Start date
May 27, 2024
Primary completion
Sep 2025 (estimated)
Completion
Sep 2025 (estimated)
Last update
Apr 25, 2025

Study contacts

Yves Levy, MD
Contact
yves.levy@aphp.fr
+33149814442

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA COVID-19 Vaccine

Start the discussion